FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG) RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...